Postgraduate Program in Epidemiology, Universidade Federal de Pelotas, Pelotas, Brazil.
Postgraduate Program Pediatrics Child Health, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.
Paediatr Perinat Epidemiol. 2020 May;34(3):278-286. doi: 10.1111/ppe.12649. Epub 2020 Mar 20.
Several studies have reported that there is an association between developmental and emotional/behavioural problems in children exposed to acetaminophen during foetal development. However, few studies have focused on development and behavioural outcomes in early life.
To test the association between prenatal exposure to acetaminophen and low neurodevelopmental performance at 24 months and behavioural/emotional problems at 48 months of life.
We used data from the 2004 Pelotas Birth Cohort, a population-based longitudinal prospective study. Neurodevelopment was evaluated at 24 months using Battelle's Developmental Inventory (BDI) (n = 3737). We assessed global function as well as each domain (personal-social, adaptative, motor, cognitive, and communication). Behavioural/emotional problems were assessed at 48 months using the Child Behaviour Checklist (CBCL) (n = 3624). We used the CBCL total, externalising, and internalising symptomatology and individual subscales (withdrawn, somatic complaints, anxious/depressed, social problems, cognitive problems, attention problems, aggressive behaviour, and rule-breaking behaviour). Acetaminophen use during pregnancy was retrospectively assessed at the perinatal follow-up. Poisson regression and multiple linear regression analyses were used to test the association, adjusting for several family and maternal sociodemographic and health factors, medication use during pregnancy, and the sex of the child.
Acetaminophen exposure during prenatal development was not associated with low neurodevelopmental performance at 24 months assessed using the BDI or to emotional and behavioural problems assessed at 48 months using the CBCL in the adjusted models.
We cannot confirm the existence of an association between acetaminophen used during pregnancy and low neurodevelopmental performance at 24 months and emotional/behavioural problems at 48 months of life based on the present results.
多项研究报告称,在胎儿发育过程中接触对乙酰氨基酚的儿童与发育和情绪/行为问题之间存在关联。然而,很少有研究关注生命早期的发育和行为结果。
测试产前暴露于对乙酰氨基酚与 24 个月时神经发育能力较低和 48 个月时行为/情绪问题之间的关联。
我们使用了 2004 年佩洛塔斯出生队列的资料,这是一项基于人群的纵向前瞻性研究。使用 Battelle 发育指数(BDI)在 24 个月时评估神经发育(n=3737)。我们评估了整体功能以及每个领域(个人-社会、适应、运动、认知和沟通)。使用儿童行为检查表(CBCL)在 48 个月时评估行为/情绪问题(n=3624)。我们使用 CBCL 总分、外化症状和内化症状以及个体分量表(退缩、躯体抱怨、焦虑/抑郁、社交问题、认知问题、注意力问题、攻击行为和破坏规则行为)。在围产期随访时回顾性评估怀孕期间对乙酰氨基酚的使用情况。使用泊松回归和多元线性回归分析调整了家庭和产妇社会人口统计学和健康因素、怀孕期间使用的药物以及儿童的性别后,测试了相关性。
在调整后的模型中,产前发育过程中接触对乙酰氨基酚与使用 BDI 评估的 24 个月时神经发育能力较低或使用 CBCL 评估的 48 个月时情绪和行为问题无关。
根据目前的结果,我们不能确认怀孕期间使用对乙酰氨基酚与 24 个月时神经发育能力较低和 48 个月时情绪/行为问题之间存在关联。